Celyad Oncology SA.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Celyad Oncology SA.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
/ 
Frequently asked questions
To buy Celyad Oncology SA. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Celyad Oncology SA. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Celyad Oncology SA. is CYAD:xbru. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Celyad Oncology SA. has its primary listing on Euronext Brussels. You can trade Celyad Oncology SA. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Celyad Oncology SA. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Celyad Oncology SA. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Celyad Oncology SA..